Asenapine is a sublingually absorbed newer second-generation antipsychotic that is approved for the treatment of schizophrenia and bipolar disorder in patients, with a lower extrapyramidal adverse effect potential. We report an adolescent boy having schizophrenia who developed an acute dystonic reaction after 4 days when the dose of asenapine was increased from 10 to 15 mg per day.
Get full access to this article
View all access options for this article.
References
1.
CitromeL: Asenapine for schizophrenia and bipolar disorder: A review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract, 63:1762–1784, 2009.
2.
De HertM, YuW, DetrauxJ, SweersK, van WinkelR, CorrellCU: Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: A systematic review and exploratory meta-analysis. CNS Drugs, 26:733–759, 2012.
3.
LiuWY: Phenothiazine-induced dystonia associated with an increase in serum creatine phosphokinase. Arch Dis Child, 54:150–151, 1979.
4.
MinassianA, YoungJW: Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opin Pharmacother, 11:2107–2115, 2010.
5.
NaranjoCA, BustoU, SellersEM, SandorP, RuizI, RobertsEA, JanecekE, DomecqC, GreenblattDJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 30:239–245, 1981.
6.
RidoutKK, RidoutSJ, PirnieLF, PuttichandaSP: Sudden-onset dystonia in a patient taking asenapine: Interaction between ciprofloxacin and asenapine metabolism. Am J Psychiatry, 172:1162–1163, 2015.
7.
Sycrest® (asenapine) Summary of Product Characteristics. Organon, 2010.
8.
Van HartenPN, HoekHW, KahnRS: Acute dystonia induced by drug treatment. BMJ, 319:623–626, 1999.
